We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.80, marking a -0.31% move from the previous day. This change was narrower than the S&P 500's 0.57% loss on the day. At the same time, the Dow lost 0.05%, and the tech-heavy Nasdaq lost 1.04%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 3.52% over the past month, lagging the Medical sector's loss of 0.85% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.92 per share. This would mark year-over-year growth of 1.05%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.76 billion, down 3.94% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.64 per share and revenue of $26.78 billion. These totals would mark changes of -8.54% and -1.82%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 11.6. Its industry sports an average Forward P/E of 17.77, so we one might conclude that Gilead Sciences is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.82. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.17 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.80, marking a -0.31% move from the previous day. This change was narrower than the S&P 500's 0.57% loss on the day. At the same time, the Dow lost 0.05%, and the tech-heavy Nasdaq lost 1.04%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 3.52% over the past month, lagging the Medical sector's loss of 0.85% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.92 per share. This would mark year-over-year growth of 1.05%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.76 billion, down 3.94% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.64 per share and revenue of $26.78 billion. These totals would mark changes of -8.54% and -1.82%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 11.6. Its industry sports an average Forward P/E of 17.77, so we one might conclude that Gilead Sciences is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.82. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.17 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.